The positive Part 1 safety data de-risks TLX591-Tx's combination profile and supports continued Phase 3 enrollment. Monitor FDA IND amendment decision and Part 2 enrollment updates as key catalysts. The differentiated liver-clearance mechanism could provide competitive advantage over existing PSMA RLTs if confirmed in larger randomized data.
Price Chart
Executive Summary
Telix presented Phase 3 ProstACT Global Part 1 safety data at ASCO 2026 for TLX591-Tx in mCRPC, showing acceptable tolerability with standard-of-care combinations and no new safety signals. The data support advancing to Part 2 randomized expansion, with FDA engagement underway for U.S. enrollment. This is a positive clinical milestone for a first-in-class rADC candidate, but the stock impact is tempered by early-stage data and no near-term approval catalyst.
Key Facts
- Part 1 data from 36 patients showed acceptable safety across all SoC combination cohorts (abiraterone, enzalutamide, docetaxel) with no new safety signals.
- All 36 patients received both doses of TLX591-Tx per protocol; hematologic events (Grade 3-4 thrombocytopenia/neutropenia) were transient and consistent with class profile.
- Dosimetry showed radiation exposure to key organs well below established safety limits; highest absorbed dose in liver (1.62-5.08 mGy/MBq), low salivary gland uptake (0.001-0.104 mGy/MBq).
- Part 2 randomized 2:1 expansion is actively dosing in Australia, New Zealand, Canada, Turkey, UK, with approvals in China, Singapore, South Korea; FDA engagement underway for U.S. IND amendment.
- TLX591-Tx is a first-in-class lutetium rADC with differentiated pharmacology (liver clearance, minimal kidney/salivary toxicity) vs. existing PSMA-targeted small molecule RLTs.
Financial Impact
No financial data provided; TLX591-Tx has not received marketing authorization in any jurisdiction.
Risk Factors
- Part 2 randomized data (n~490) may not replicate Part 1 safety profile or show efficacy benefit vs. SoC alone.
- Regulatory delays in U.S. IND amendment could slow enrollment and timeline.
- Competition from approved PSMA-targeted RLTs (e.g., Pluvicto) with established commercial presence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304754 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $12.83 $11.95 | ▼ −6.86% | ▼ −8.99% | $10.55 (−17.77%) |
Sep 14, 2026 18d ago | Press Release | $11.78 $11.31 | ▼ −3.99% | ▼ −4.10% | $10.55 (−10.44%) |
Sep 2, 2026 4w ago | 6-K | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Sep 1, 2026 4w ago | Press Release | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Aug 20, 2026 6w ago | 6-K | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Aug 20, 2026 6w ago | Press Release | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Jul 30, 2026 9w ago | Press Release | $9.89 $11.52 | ▲ +16.48% | ▲ +12.97% | $10.55 (+6.67%) |
Jul 21, 2026 10w ago | Press Release | $10.32 $10.10 | ▼ −2.13% | ▲ +0.27% | $10.55 (+2.23%) |
Jul 21, 2026 10w ago | 6-K | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
Jul 20, 2026 10w ago | Press Release | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access